All In Biotech

Drug Trial Radar · NCT04673942

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Mar 29, 2021

Primary completion

Dec 1, 2026

Study completion Mar 1, 2027

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.

Conditions

  • Solid Tumor, Adult
  • Cancer
  • Neoplasms
  • Sarcoma
  • Sarcoma,Soft Tissue
  • Chondrosarcoma

Interventions

  • AdAPT-001Biological

    Oncolytic virus administered by intratumoral injection

  • Checkpoint Inhibitor, ImmuneDrug

    Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: 28 days
  2. Maximum tolerated doseTime frame: 28 days
  3. Safety of a multiple dose regimen of AdAPT-001Time frame: 6 months
  4. Anti-tumor activity of the two-arm dose regimens of AdAPT-001 in Phase 2Time frame: 6 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • California Cancer Associates for Research and Excellence, cCARE

    San Marcos, California

  • Providence Saint John's Health Center

    Santa Monica, California

  • Cleveland Clinic

    Cleveland, Ohio

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.